Acute Migraine

Midwest CEPAC

ICER will assess the comparative clinical effectiveness and value of treatments for acute migraine, including: two oral CGRP receptor antagonists, rimegepant (Biohaven) and ubrogepant (Allergan); and a 5-HT1f agonist lasmiditan (Eli Lilly). All three of these agents are under FDA review with an anticipated decision in the final quarter of 2019. The report will be reviewed during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) in January 2020.

For questions, please contact Ellie Adair, Program Manager, at eadair@icer-review.org.

Associated Meetings

January 23, 2020 10am - 4pm CT

Sheraton Suites Chicago O’Hare
6501 Mannheim Road
Rosemont, IL 60018

The Midwest CEPAC will convene to review ICER's assessment of acute migraine treatments.


Key Dates

Associated Materials

06/07/2019 – 06/25/2019

06/28/2019

06/28/2019 – 07/19/2019
Public Comments

06/28/2019

07/29/2019
Revised Scoping Document

09/06/2019
Research Protocol

09/24/2019
Model Analysis Plan

11/07/2019
Draft Evidence Report

11/07/2019
Draft Voting Questions

11/07/2019 – 12/06/2019
Public Comments

01/08/2020
Revised Voting Questions

01/08/2020
Response to Public Comments

01/08/2020
Meeting Agenda

01/08/2020
Evidence Report

01/23/2020
Evidence Presentation

02/13/2020
Final Evidence Report and Meeting Summary

02/13/2020
Report-at-a-Glance